## Edgar Filing: Novocure Ltd - Form 4

Novocure L Form 4	td										
May 03, 201	17										
FORM	14	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				~~~			OMB AF	PROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMMISSION	OMB Number:	3235-0287	
Check th if no lon subject t Section Form 4 o Form 5 obligatio may con <i>See</i> Instr 1(b).	ger o 16. or Filed pur ons tinue.	suant to S	Expires: January 31, 2005 Estimated average burden hours per response 0.5								
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Palti Yoram			2. Issuer Name <b>and</b> Ticker or Trading Symbol Novocure Ltd [NVCR]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (1	Middle)	3. Date of Earliest Transaction				(Check	all applicable	)		
C/O NOVOCURE INC., 20 VALLEY STREAM, PKWY SUITE 300			(Month/Day/Year) 05/01/2017					X Director 10% Owner X Officer (give title Other (specify below) Chief Technology Officer			
				Amendment, Date Original l(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>			
(City)	(State)	(Zip)	Tah	la I - Non-I	Darivativa	Secu	ritios A ca	uired, Disposed of,	or Bonoficial	ly Owned	
1.Title of Security (Instr. 3)		action Date 2A. Deemed		3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Ondinamy				Code V	Amount	(D)	Price \$	(Instr. 3 and 4)			
Ordinary Shares	05/01/2017			S	4,000	D	11.444 (1)	95,825	D		
Ordinary Shares	05/02/2017			S	4,000	D	\$ 11.836 (2)	91,825	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

### Edgar Filing: Novocure Ltd - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	′ (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
here and a second second second	Director	10% Owner	Officer	Other		
Palti Yoram C/O NOVOCURE INC., 20 VALLEY STREAM PKWY SUITE 300 MALVERN, PA 19355	Х		Chief Technology Officer			
Signatures						
By: /s/ Todd Longsworth, Attorney in fact for Yoram Palti		05/03/2017				
<u>**</u> Signature of Reporting Person		Date				

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On May 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from \$11.20 to \$11.80. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and

prices at which the transaction was effected.

On May 2, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from \$11.725 to \$11.950. The price reported above reflects the weighted average sale price. Professor Palti hereby

(2) Infects ranging from \$11.725 to \$11.950. The price reported above reflects the weighted average sale price. Professor Path hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.